title: Characterisation of the neuropeptide Y receptor that mediates feeding in the rat: a role for the Y5 receptor?
abstract: Food intake was measured in freely fed rats following intracerebroventricular administration of neuropeptide Y (NPY) and several of its analogues and antagonists to investigate the hypothesis that the NPY Y5 receptor mediates feeding. Rat NPY (rNPY), rNPY(2-36) and rNPY(3-36) produced similar feeding responses over the dose range 0.7-7.0 nmol. Rat peptide YY (rPYY) was more potent and at least as efficacious as rNPY. [Leu31 Pro34]-rNPY (agonist potency: Y1 > Y5 > Y4 = y6) and human pancreatic polypeptide (hPP) produced flatter dose-response curves, suggesting partial agonism at the receptor(s). rNPY(13-36) (agonist potency: Y2 > Y5) had little activity and rPP was inactive. [D-Trp32]-NPY was a weak orexigenic agent given alone and, consistent with partial agonism, it markedly antagonised the response to porcine NPY (pNPY). Similarly, the receptor antagonist (Y1 > Y4) 1229U91 stimulated feeding slightly, and markedly inhibited rNPY-induced feeding. In contrast to a previous report, BIBP 3226 (70 nmol), another Y1 receptor antagonist, failed to inhibit the response to rNPY. Our data in vivo are inconsistent with findings that hPP, [Leu31 Pro34]-rNPY and [D-Trp32]-rNPY are full agonists at the rat cloned Y5 receptor. Thus, whilst the Y5 receptor may be involved, its participation as the sole receptor mediating the orexigenic action of NPY in the rat remains unproven.
authors.affiliation: Department of Vascular Biology, SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK. Andrea_Haynes-1@sbphrd.com
authors.forename: A C
authors.initials: AC
authors.lastname: Haynes
authors.forename: J R
authors.initials: JR
authors.lastname: Arch
authors.forename: S
authors.initials: S
authors.lastname: Wilson
authors.forename: S
authors.initials: S
authors.lastname: McClue
authors.forename: R E
authors.initials: RE
authors.lastname: Buckingham
mesh_terms: D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D004435:Eating / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D009478:Neuropeptide Y / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D010446:Peptide Fragments / Q000008:administration & dosage; D019894:Peptide YY / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017476:Receptors, Neuropeptide Y / Q000145:classification / Q000187:drug effects / Q000502:physiology*; D013552:Swine
chemical_list: C097287:1229U91; C092926:BIBP 3226; D009478:Neuropeptide Y; D010446:Peptide Fragments; D010456:Peptides, Cyclic; D017476:Receptors, Neuropeptide Y; C100568:neuropeptide Y5 receptor; D019894:Peptide YY; D001120:Arginine